Skip to Main Content


Skip Nav Destination

Acute Leukemias

November 5, 2021

A collection of features and news articles published in ASH Clinical News related to acute leukemias.


Venetoclax Proves Active in Newly Diagnosed AML

Two studies investigating the activity and safety of the BCL-2 inhibitor venetoclax support its use as part of first-line treatment in adults with newly diagnosed acute myeloid leukemia (AML)....

AlloHCT Outcomes Improved in Adults With ALL

Outcomes for allogeneic hematopoietic cell transplantation (alloHCT) for acute lymphoblastic leukemia (ALL) have improved in the past 30 years, according to study findings published in Blood Advances....

Ivosidenib/Azacitidine Combo Improved Overall Survival in IDH1-Mutated AML

The combination of the IDH1 inhibitor ivosidenib and azacitidine demonstrated significant clinical benefit in patients with newly diagnosed IDH1-mutated acute myeloid leukemia...

Code Status Transition in High-Risk AML Happening Near End of Life

Patients with high-risk acute myeloid leukemia (AML) often had code change status transitions occur very near the end of life...

Azacitidine and Decitabine Garner Comparable Clinical Outcomes Among Older, Unfit Patients With AML

Treatment responses and survival outcomes were comparable among older, unfit patients with acute myeloid leukemia (AML) who received either of two hypomethylating agents (HMAs), azacitidine or decitabine...

Venetoclax Combination Therapy Works Better in Some AML Subtypes Than Others

Patients with TP53-mutated acute myeloid leukemia (AML) had a comparably good overall survival (OS) time when treated with the BCL-2 inhibitor venetoclax in combination with hypomethylating agents...

AML MRD Testing By NGS Identifies Adults At High Relapse Risk After Allogeneic Transplantation

Measurable residual disease (MRD) testing using next-generation sequencing (NGS) in adult patients with acute myeloid leukemia (AML) in first complete remission (CR1) can predict those at highest risk of relapse...

Factors That May Increase Thrombosis Risk in AML Identified

In patients with acute myeloid leukemia (AML), risk factors for venous thromboembolism (VTE) include male sex, prior history of thrombosis, good Eastern Cooperative Oncology Group performance status (ECOG PS)...

Anti-CD7 CAR T Cells Show Efficacy and Safety in Relapsed/Refractory T-ALL and T-LBL

CD7-targeted chimeric antigen receptor (7CAR) T cells were found to be safe and effective in the treatment of relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma...

Venetoclax and Azacitidine Combo Confers Similar Outcomes in Older Patients With AML Irrespective of FLT3 Mutation Status

A combination regimen comprising venetoclax plus azacitidine appears to have similar efficacy as a frontline strategy for treatment-naïve patients with acute myeloid leukemia...


Connect with us:

September 2022


Close Modal

or Create an Account

Close Modal
Close Modal